Orally disintegrating tablet with rivastigmine tartrate
A technology for rivastigmine tartrate and oral disintegrating tablets, which is applied in the directions of drug combination, nervous system diseases, ester active ingredients, etc., can solve the problems of difficulty in taking medicine, inconvenient use, etc., and achieves good taste, convenient taking and compatibility. good effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0032] The orally disintegrating tablet of rivastigmine tartrate comprises main ingredients and auxiliary materials, and is characterized in that it is formulated according to the following weight percentages: 0.6% of main ingredients and 99.4% of auxiliary materials.
[0033] Rivastigmine tartrate 1.5g (0.6%)
[0034] Microcrystalline Cellulose 55g (22%)
[0035] Mannitol 123.5g (49.4%)
[0036] Lactose 52g (20.8%)
[0037] Anhydrous citric acid 1.5g (0.6%)
[0038] Cross-linked polyvinylpyrrolidone 7.5g (3%)
[0039] Cyclamate 3g (1.2%)
[0040] Menthol 2.5g (1%)
[0041] Micronized silica gel 2.5g(1%)
[0042] Magnesium Stearate 1g (0.4%)
[0043] A total of 1000 tablets were produced
[0044] Among them, lactose and mannitol are fillers, microcrystalline cellulose and cross-linked polyvinylpyrrolidone are disintegrants, anhydrous citric acid, cyclamate and menthol are flavoring agents, magnesium stearate is lubricant, and micronized silica gel is Glidant.
[0045...
Embodiment 2
[0054] The orally disintegrating tablet of rivastigmine tartrate comprises main ingredients and auxiliary materials, and is characterized in that it is formulated according to the following weight percentages: 0.12% of main ingredients and 99.88% of auxiliary materials.
[0055] Rivastigmine Tartrate 3.0g(0.12%)
[0056] Microcrystalline Cellulose 37g (14.8%)
[0057] Mannitol 150g (60%)
[0058] Lactose 40g (16%)
[0059] Anhydrous citric acid 1.5g (0.6%)
[0060] Cross-linked polyvinylpyrrolidone 10g (4%)
[0061] Cyclamate 2g (0.8%)
[0062] Menthol 2g (0.8%)
[0063]Micropowder silica gel 3g(1.2%)
[0064] Magnesium Stearate 1.5 (0.6%)
[0065] A total of 1000 tablets were produced
[0066] The preparation method of the rivastigmine tartrate orally disintegrating tablet of the present invention is the same as in Example 1, and the rivastigmine tartrate orally disintegrating tablet with a tablet weight of 250 mg is obtained.
[0067] test results:
[0068] Tablet ...
Embodiment 3
[0072] The orally disintegrating tablet of rivastigmine tartrate comprises main ingredients and auxiliary materials, and is characterized in that it is formulated according to the following weight percentages: 1.6% of main ingredients and 98.4% of auxiliary materials.
[0073] Rivastigmine tartrate 4g (1.6%)
[0074] Microcrystalline Cellulose 70g (28%)
[0075] Mannitol 92.75g (37.1%)
[0076] Lactose 60g (24%)
[0077] Anhydrous citric acid 2g (0.8%)
[0078] Cross-linked polyvinylpyrrolidone 12.5g (5%)
[0079] Cyclamate 2.5g(1%)
[0080] Menthol 0.25g (0.1%)
[0081] Micronized silica gel 4g(1.6%)
[0082] Magnesium Stearate 2g (0.8%)
[0083] A total of 1000 tablets were produced
[0084] The preparation method of the rivastigmine tartrate orally disintegrating tablet of the present invention is the same as in Example 1, and the rivastigmine tartrate orally disintegrating tablet with a tablet weight of 250 mg is obtained.
[0085] test results:
[0086] Tablet h...
PUM
| Property | Measurement | Unit |
|---|---|---|
| hardness | aaaaa | aaaaa |
| hardness | aaaaa | aaaaa |
| hardness | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More